216 related articles for article (PubMed ID: 33747979)
1. Combination With Tomatidine Improves the Potency of Posaconazole Against
Rocha-Hasler M; de Oliveira GM; da Gama AN; Fiuza LFA; Fesser AF; Cal M; Rocchetti R; Peres RB; Guan XL; Kaiser M; Soeiro MNC; Mäser P
Front Cell Infect Microbiol; 2021; 11():617917. PubMed ID: 33747979
[TBL] [Abstract][Full Text] [Related]
2. Successful Aspects of the Coadministration of Sterol 14α-Demethylase Inhibitor VFV and Benznidazole in Experimental Mouse Models of Chagas Disease Caused by the Drug-Resistant Strain of Trypanosoma cruzi.
Guedes-da-Silva FH; Batista DDGJ; Da Silva CF; Pavão BP; Batista MM; Moreira OC; Souza LRQ; Britto C; Rachakonda G; Villalta F; Lepesheva GI; Soeiro MNC
ACS Infect Dis; 2019 Mar; 5(3):365-371. PubMed ID: 30625275
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of new 1,2,3-triazoles derived from eugenol and analogues with in vitro and in vivo activity against Trypanosoma cruzi.
Reis RCFM; Dos Santos EG; Benedetti MD; Reis ACC; Brandão GC; Silva GND; Diniz LA; Ferreira RS; Caldas IS; Braga SFP; Souza TB
Eur J Med Chem; 2023 Oct; 258():115622. PubMed ID: 37441850
[TBL] [Abstract][Full Text] [Related]
4. Benznidazole and posaconazole in experimental Chagas disease: positive interaction in concomitant and sequential treatments.
Diniz Lde F; Urbina JA; de Andrade IM; Mazzeti AL; Martins TA; Caldas IS; Talvani A; Ribeiro I; Bahia MT
PLoS Negl Trop Dis; 2013; 7(8):e2367. PubMed ID: 23967360
[TBL] [Abstract][Full Text] [Related]
5. Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.
Ferreira de Almeida Fiuza L; Peres RB; Simões-Silva MR; da Silva PB; Batista DDGJ; da Silva CF; Nefertiti Silva da Gama A; Krishna Reddy TR; Soeiro MNC
Eur J Med Chem; 2018 Apr; 149():257-268. PubMed ID: 29501946
[TBL] [Abstract][Full Text] [Related]
6. Antitrypanosomal Treatment with Benznidazole Is Superior to Posaconazole Regimens in Mouse Models of Chagas Disease.
Khare S; Liu X; Stinson M; Rivera I; Groessl T; Tuntland T; Yeh V; Wen B; Molteni V; Glynne R; Supek F
Antimicrob Agents Chemother; 2015 Oct; 59(10):6385-94. PubMed ID: 26239982
[TBL] [Abstract][Full Text] [Related]
7. Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial.
Morillo CA; Waskin H; Sosa-Estani S; Del Carmen Bangher M; Cuneo C; Milesi R; Mallagray M; Apt W; Beloscar J; Gascon J; Molina I; Echeverria LE; Colombo H; Perez-Molina JA; Wyss F; Meeks B; Bonilla LR; Gao P; Wei B; McCarthy M; Yusuf S;
J Am Coll Cardiol; 2017 Feb; 69(8):939-947. PubMed ID: 28231946
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo activity of voriconazole and benznidazole combination on trypanosoma cruzi infection models.
Gulin JEN; Eagleson MA; López-Muñoz RA; Solana ME; Altcheh J; García-Bournissen F
Acta Trop; 2020 Nov; 211():105606. PubMed ID: 32598923
[TBL] [Abstract][Full Text] [Related]
9. Limited Ability of Posaconazole To Cure both Acute and Chronic Trypanosoma cruzi Infections Revealed by Highly Sensitive In Vivo Imaging.
Francisco AF; Lewis MD; Jayawardhana S; Taylor MC; Chatelain E; Kelly JM
Antimicrob Agents Chemother; 2015 Aug; 59(8):4653-61. PubMed ID: 26014936
[TBL] [Abstract][Full Text] [Related]
10. Listen to what the animals say: a systematic review and meta-analysis of sterol 14-demethylase inhibitor efficacy for in vivo models of Trypanosoma cruzi infection.
Bisio MMC; Jurado Medina LS; García-Bournissen F; Gulin JEN
Parasitol Res; 2024 Jun; 123(6):248. PubMed ID: 38904688
[TBL] [Abstract][Full Text] [Related]
11. Sesquiterpene lactone potentiates the immunomodulatory, antiparasitic and cardioprotective effects on anti-Trypanosoma cruzi specific chemotherapy.
Gonçalves-Santos E; Vilas-Boas DF; Diniz LF; Veloso MP; Mazzeti AL; Rodrigues MR; Oliveira CM; Fernandes VHC; Novaes RD; Chagas-Paula DA; Caldas IS
Int Immunopharmacol; 2019 Dec; 77():105961. PubMed ID: 31685438
[TBL] [Abstract][Full Text] [Related]
12. Impact of levamisole in co-administration with benznidazole on experimental Chagas disease.
Rocha Simões-Silva M; Brandão Peres R; Britto C; Machado Cascabulho C; de Melo Oliveira G; Nefertiti da Gama A; França da Silva C; Lima da Costa K; Finamore Araújo P; Diego de Souza Campos J; Meuser Batista M; Cristina Demarque K; da Cruz Moreira O; de Nazaré Correia Soeiro M
Parasitology; 2019 Jul; 146(8):1055-1062. PubMed ID: 31046850
[TBL] [Abstract][Full Text] [Related]
13. Drug repurposing strategy against Trypanosoma cruzi infection: In vitro and in vivo assessment of the activity of metronidazole in mono- and combined therapy.
Simões-Silva MR; De Araújo JS; Oliveira GM; Demarque KC; Peres RB; D'Almeida-Melo I; Batista DGJ; Da Silva CF; Cardoso-Santos C; Da Silva PB; Batista MM; Bahia MT; Soeiro MNC
Biochem Pharmacol; 2017 Dec; 145():46-53. PubMed ID: 28870526
[TBL] [Abstract][Full Text] [Related]
14. The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole.
Ferraz ML; Gazzinelli RT; Alves RO; Urbina JA; Romanha AJ
Antimicrob Agents Chemother; 2007 Apr; 51(4):1359-64. PubMed ID: 17220408
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo drug combination for the treatment of Trypanosoma cruzi infection: A multivariate approach.
Strauss M; Rodrigues JHS; Lo Presti MS; Bazán PC; Báez AL; Paglini-Oliva P; Nakamura CV; Bustamante JM; Rivarola HW
Exp Parasitol; 2018 Jun; 189():19-27. PubMed ID: 29726395
[TBL] [Abstract][Full Text] [Related]
16. Repurposing Strategy of Atorvastatin against Trypanosoma cruzi:
Araujo-Lima CF; Peres RB; Silva PB; Batista MM; Aiub CAF; Felzenszwalb I; Soeiro MNC
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29987140
[TBL] [Abstract][Full Text] [Related]
17. Antitrypanosomal Activity of Sterol 14α-Demethylase (CYP51) Inhibitors VNI and VFV in the Swiss Mouse Models of Chagas Disease Induced by the Trypanosoma cruzi Y Strain.
Guedes-da-Silva FH; Batista DG; Da Silva CF; De Araújo JS; Pavão BP; Simões-Silva MR; Batista MM; Demarque KC; Moreira OC; Britto C; Lepesheva GI; Soeiro MN
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167559
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo antiparasitic activity of Physalis angulata L. concentrated ethanolic extract against Trypanosoma cruzi.
Meira CS; Guimarães ET; Dos Santos JA; Moreira DR; Nogueira RC; Tomassini TC; Ribeiro IM; de Souza CV; Ribeiro Dos Santos R; Soares MB
Phytomedicine; 2015 Oct; 22(11):969-74. PubMed ID: 26407938
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the anti-Trypanosoma cruzi activity in vitro and in vivo of silibinin and silibinin in association to benznidazole.
Torchelsen FKVDS; Silva TM; Milagre MM; Silva RR; Reis LES; Branquinho RT; Silva GN; de Lana M
Parasitol Res; 2021 Apr; 120(4):1511-1517. PubMed ID: 33236174
[TBL] [Abstract][Full Text] [Related]
20. Development of a Fluorescence-based Trypanosoma cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas Disease.
Riley J; Brand S; Voice M; Caballero I; Calvo D; Read KD
PLoS Negl Trop Dis; 2015 Sep; 9(9):e0004014. PubMed ID: 26394211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
